Plateforme NeuroTimone (PFNT)

La PFNT (Plateforme NeuroTimone) est un ensemble cohérent d'outils d'exploration en neurobiologie permettant des investigations aux échelles moléculaires, cellulaires et intégrées.

A la Une

  1. 5th Scientific Annual Conference - Institut Cancer et Immunologie (ICI)

    On 4 April, Nora Essakhi, Roberta Stacchini and Alexandre Bertucci, PhD students in the GlioME team, presented their poster at the 5th Scientific Annual Conference - Institut Cancer et Immunologie (ICI) on the theme of "CAR T cells, advances in cellular engineering and future challenges in cancer therapy".

    Nora's work on "GD3, a promising therapeutic target for CAR-T cells against glioblastoma stem cells", was recognised by the scientific committee, which awarded her the prize for best poster. Well done Nora!

     

  2. GlioME team: A new review is out

    The review "GD3 ganglioside is a promising therapeutic target for glioma patients" is now published in Neuro-oncology Advances.  

    Congratulations to Victoria Hein, Nathalie Baeza-Kallee, Alexandre Bertucci, Carole Colin, Aurélie Tchoghandjian, Dominique Figarella-Branger, Emeline Tabouret for this work. 

     

  3. New trainee - Team 4

    Salma Laftimi, a L3 student at AMU, joined Team 4 for her internship. She will stay with us for 1 month.

    Welcome!

  4. Welcome to Nasab Reda, new post-doc in Team 6

    Dr Nasab Reda joins Team 6 as a post-doctoral researcher on a one-year project with an industrial partner.

    She will be in charge of setting up a cellular model to study the effects of modulating a receptor of interest to the partner.

  5. Nicolas got a fellowship from Novartis

    Congratulations to Nicolas Vermeersch, PhD student in Teams 4 and 6, who received a "bourse de recherche pour l'avancement de l'innovation en neurosciences de Novartis", BRAINNS.
    Well done!

  6. Céline Gomis Stagiaire dans l'équipe 7

    Céline a rejoint l'équipe Neurocyto le 04 mars 2024.

    Elle va étudier les microtubules et leur mécanisme de régénération sur des cultures primaires neuronales.

    Elle est en 3ième année de BUT génie biologique parcours biologie médicale et biotechnologies à Clermont-Ferrand.

  7. CNRS welcome day for Chiara and Maud

    Chiara Bastiancich (GlioME) and Maud Gratuze (SynapTau) participated to the CNRS welcome day in Paris. 

    It was a great opportunity for them to meet the 770 other new recruits of the CNRS in 2023 and to get to know their new scientific ally better!

  8. Brain Awareness Week 2024: SynapTau team

    As part of the Brain Awareness Week 2024, Maud Gratuze from the "Synaptic degeneration and Gliosis" team has been invited to contribute to the webinar: "France Alzheimer: Hope in Research" organized by France Alzheimer association which took place on Tuesday, March 12th. 

    The videos will soon be on the France Alzheimer association's YouTube channel.

Pages

L'INP en chiffres

  • 126 membres
  • 44 chercheurs
  • 48 chercheurs assistants
  • 12 post-doctorants
  • 11 doctorants

 

HDR defense - Team 4 OligOld

Dr. Sarah Moyon, team leader of OligOld (team 4) defended her HDR on Friday, February 23rd, 2024, in front of the jury members: Nicolas Andre (APHM, AMU), Pascale Durbec (IBDM, AMU), Patrice Roll (MMG, AMU), Carlos Parras (ICM, Paris), Maria-Cecilia Angulo (IPNP, Paris) and Anna Williams (University of Edinburgh, UK).

Indéfini

Agenda

19 avr 2024 14:30

Team 11: Guest seminar : Valérie Delague

Salle 52 (5e étage aile rouge - 5th floor red section)

  • Point vulgarisation assuré par Gaelle Capraz sur "La poussière de cellules".

 

  • Valérie Delague is invited by Gaelle Capraz

 

  • Valerie Delague is a human geneticist and molecular biologist. While setting-up and leading the Molecular Genetics lab, during 7 years (1997-2004), at the Medical Genetics Unit (UGM) at Saint-Joseph University in Beirut, she obtained her PhD in Genetics in 2001. Since 2004, she is an Inserm Researcher in the MMG Research Unit, where she is focusing her research on Charcot-Marie-Tooth disease and other Inherited Peripheral Neuropathies, as an Inserm Research Director (DR2 Inserm) and leader of her own research group, “Genetics and physiopathology of Inherited Peripheral Neuropathies (IPN)”. She has a strong expertise in the genetics of this class of neuromuscular diseases with 62 publications, including the description of 3 new disease causing genes in the pathology. She is well-known for expertise in the field of recessive diseases in a context of consanguinity. She is also responsible of the Genomics and Bioinformatics Platform at the MMG.
  • She will present the platform's activities and technologies "Genomics and Bioinformatics Marseille"
17 mai 2024 14:30

Team 2: Matthew Lennol

Amphi CERIMED

Matthew Lennol

"Deciphering apolipoprotein E-associated alterations in Alzheimer's Disease"

APOE, the gene encoding the apolipoprotein E (apoE) protein, is the most prominent genetic risk factor for sporadic AD. Although the APOE ε4 allelic variant is linked to increased risk of AD, it is likely that all isoforms are participating in the pathology to some degree. Other apoE-related proteins, including receptors and competitive ligands,  such as reelin, may also play yet undescribed roles in AD. The following studies aim to characterise alterations in both apoE and reelin patterns in the cerebrospinal fluid of AD patients with the aim of developing new potential biomarkers for the pathology. We also describe a relatively unknown apoE receptor family member, LRP3, to try and elucidate novel pathways that may be participating in AD.

Partenaires